Bullboard Post History

by enriquesuave

Order by:

V.TLT	RE:RE:The Data We must also not dismiss the fact that I believe 5 patients were wrongly... April 8, 2022
V.TLT	Accelerated Approvals https://www.fiercebiotech.com/biotech/fda-oncology-chief-eyes-accelerated... April 7, 2022
V.TLT	RE:The Data Simply not enough data at 360 days and 450 days. At both of these time... April 7, 2022
V.TLT	RE:Only 5 new patients treated in the last four months December to March was smack in the middle of Omicron and hospitals were once... April 7, 2022
V.TLT	RE:RE:RE:RE:Roger buying … Roger deserves his shares and he has bought in the open market with his own... April 7, 2022
V.TLT	RE:FDA The data is actually better than it seems upon close examination. ... April 7, 2022
V.TLT	FDA The FDA can only like the Novel method used here which is basically a ONE and... April 7, 2022
V.TLT	RE:RE:RE:RE:RE:Break through. That is 99.9% cell kill using Rutherin and x-ray activation. Incredible... April 6, 2022
V.TLT	RE:RE:RE:RE:Break through. Maybe we get a Quarterly report with financials end of April and more details... April 6, 2022
V.TLT	RE:Only needing 3 more CR to match Merck's KEYTRUDA At 360 days and 450 days, there is 47% pending or 18 patients pending. ... April 6, 2022
V.TLT	RE:RE:Heads Should Roll "Conclusion: Study II has delivered significant clinical results to... April 5, 2022
V.TLT	RE:Still Early Some more colour I will look at the next 270 day results readout of... April 5, 2022
V.TLT	Still Early But in next few months as we get a bit more data picture will be more clear... April 5, 2022
V.TLT	RE:The 23 Optimized Patients Sounds very precise Eoganacht. Of the 4 Nonresponders at 90 days, that... April 5, 2022
V.TLT	Financials due end of April I believe. We may get Quarterly at the same time as financials, perhaps more... April 5, 2022
V.TLT	RE:Comparisons of single agents From the percentages used, we can see that they are counting the 4 patients... April 5, 2022
V.TLT	Comparisons of single agents 90 days... April 5, 2022
V.TLT	RE:TLT Conclusion - On a good track... Maybe we get BTD this week and surprise market . Initial sell off from... April 5, 2022
V.TLT	RE:RE:71%-82% potential still at reach Excellent results as we beat Keytruda by far. 60% of evaluable patients are... April 5, 2022
V.TLT	RE:RE:Why we are not a bunch of happy investors is besides me. MIBC might be another indication making them own the Bladder Cancer market in... March 31, 2022

Become a member today, It's free!

Bullboard Post History

by enriquesuave

RE:RE:The Data

Accelerated Approvals

RE:The Data

RE:Only 5 new patients treated in the last four months

RE:RE:RE:RE:Roger buying …

RE:FDA

FDA

RE:RE:RE:RE:RE:Break through.

RE:RE:RE:RE:Break through.

RE:Only needing 3 more CR to match Merck's KEYTRUDA

RE:RE:Heads Should Roll

RE:Still Early

Still Early

RE:The 23 Optimized Patients

Financials due end of April

RE:Comparisons of single agents

Comparisons of single agents

RE:TLT Conclusion - On a good track...

RE:RE:71%-82% potential still at reach

RE:RE:Why we are not a bunch of happy investors is besides me.

Featured News Links

Significant New Silver Discoveries in the Famous Keno Hill District in the Yukon

This Gambling Tech Stock is Future-Proofing the World’s Casinos and has No Direct Competition

Silvercorp to Acquire Adventus, Creating a Geographically Diversified Mining Company

Revolutionary Tech Company Announces Fourth Quarter and Full Year 2023 Results

Drill Permit Approval Received for New Mexico Lithium Project

This profitable gold stock is on its way up

Mullen Group Ltd. Reports 2024 First Quarter Financial Results

Featured Company

Lucky Minerals Inc V.LKY

Become a member today, It's free!

Sign In

Send my password

Become a member today, It's free!

Bullboard Post History

by enriquesuave

Featured News Links

Featured Company